We use cookies

This website uses cookies. If you do not want these cookies you can disable them here. Read more about our cookie statement.

CompanyIt's our mission to have a turnkey solution for bringing drugs to targeted cells

It's our mission to have a turnkey solution for bringing drugs to targeted cells

Team

Pioneering in the field of Fibrobody-Drug Conjugates

More on Team
Location and facilities

More on Location and facilities
Careers

We are always in search of new colleagues

More on Careers

We are the first to develop Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases.

What’s new at LinXis

Image Meet us at BuiEquity 2025
Event

Meet us at BuiEquity 2025

12 May 2025

On May 13th and 14th LinXis will attend the 2025 BioEquity Event in Bruges, Belgium.
Image LinXis publishes key paper on lead Fibrobody® in EJNMMI
Publication

LinXis publishes key paper on lead Fibrobody® in EJNMMI

6 March 2025

Read all about the preclinical validation of our lead Fibrobody® in the European Journal of Nuclear Medicine and Molecular Imaging.
Image LinXis receives TKI-PPP grant
Science

LinXis receives TKI-PPP grant

5 March 2025

With a total budget close to EUR1 million, the FibroTarget project aims to develop Fibrobody-Drug Conjugates (FDCs) for the treatment of pulmonary fibrosis.